Metabolic Syndrome — Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Citation(s)
Adams-Huet B, Devaraj S, Siegel D, Jialal I Increased adipose tissue insulin resistance in metabolic syndrome: relationship to circulating adipokines. Metab Syndr Relat Disord. 2014 Dec;12(10):503-7. doi: 10.1089/met.2014.0092. Epub 2014 Aug 27.
Akhtar MS, Ramzan A, Ali A, Ahmad M Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. Int J Food Sci Nutr. 2011 Sep;62(6):609-16. doi: 10.3109/09637486.2011.560565. Epub 2011 Apr 18.
Athyros VG, Mikhailidis DP High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice. J Diabetes Complications. 2016 Jan-Feb;30(1):9-11. doi: 10.1016/j.jdiacomp.2015.07.012. Epub 2015 Jul 17.
Blaschke TF, Osterberg L, Vrijens B, Urquhart J Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275-301. doi: 10.1146/annurev-pharmtox-011711-113247. Epub 2011 Sep 19. Review.
Cerezo C, Segura J, Praga M, Ruilope LM Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. Curr Hypertens Rep. 2013 Jun;15(3):196-203. doi: 10.1007/s11906-013-0337-4. Review.
Chen TS, Liou SY, Chang YL Supplementation of Emblica officinalis (Amla) extract reduces oxidative stress in uremic patients. Am J Chin Med. 2009;37(1):19-25.
D'souza JJ, D'souza PP, Fazal F, Kumar A, Bhat HP, Baliga MS Anti-diabetic effects of the Indian indigenous fruit Emblica officinalis Gaertn: active constituents and modes of action. Food Funct. 2014 Apr;5(4):635-44. doi: 10.1039/c3fo60366k. Review.
Faizal P, Suresh S, Satheesh Kumar R, Augusti KT A study on the hypoglycemic and hypolipidemic effects of an ayurvedic drug Rajanyamalakadi in diabetic patients. Indian J Clin Biochem. 2009 Jan;24(1):82-7. doi: 10.1007/s12291-009-0014-1. Epub 2009 May 8.
Grundy SM Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012 Feb 14;59(7):635-43. doi: 10.1016/j.jacc.2011.08.080. Review.
Kim HY, Okubo T, Juneja LR, Yokozawa T The protective role of amla (Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. Br J Nutr. 2010 Feb;103(4):502-12. doi: 10.1017/S0007114509991978. Epub 2009 Nov 2.
Krishnaveni M, Mirunalini S Therapeutic potential of Phyllanthus emblica (amla): the ayurvedic wonder. J Basic Clin Physiol Pharmacol. 2010;21(1):93-105. Review.
Nain P, Saini V, Sharma S, Nain J Antidiabetic and antioxidant potential of Emblica officinalis Gaertn. leaves extract in streptozotocin-induced type-2 diabetes mellitus (T2DM) rats. J Ethnopharmacol. 2012 Jun 26;142(1):65-71.
Nazish I, Ansari SH Emblica officinalis - Anti-obesity activity. J Complement Integr Med. 2017 Dec 5;15(2). pii: /j/jcim.2018.15.issue-2/jcim-2016-0051/jcim-2016-0051.xml. doi: 10.1515/jcim-2016-0051.
O'Neill S, O'Driscoll L Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015 Jan;16(1):1-12. doi: 10.1111/obr.12229. Epub 2014 Nov 18. Review.
Park SE, Park CY, Sweeney G Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit Rev Clin Lab Sci. 2015;52(4):180-90. doi: 10.3109/10408363.2015.1023429. Epub 2015 Jun 4. Review.
Patel SS, Goyal RK, Shah RS, Tirgar PR, Jadav PD Experimental study on effect of hydroalcoholic extract of Emblica officinalis fruits on glucose homeostasis and metabolic parameters. Ayu. 2013 Oct;34(4):440-4. doi: 10.4103/0974-8520.127731.
Samson SL, Garber AJ Metabolic syndrome. Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23. doi: 10.1016/j.ecl.2013.09.009. Review.
Usharani P, Fatima N, Muralidhar N Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study. Diabetes Metab Syndr Obes. 2013 Jul 26;6:275-84. doi: 10.2147/DMSO.S46341. Print 2013.
Variya BC, Bakrania AK, Patel SS Emblica officinalis (Amla): A review for its phytochemistry, ethnomedicinal uses and medicinal potentials with respect to molecular mechanisms. Pharmacol Res. 2016 Sep;111:180-200. doi: 10.1016/j.phrs.2016.06.013. Epub 2016 Jun 15. Review.
Vasudeva N, Yadav N, Sharma SK Natural products: a safest approach for obesity. Chin J Integr Med. 2012 Jun;18(6):473-80. doi: 10.1007/s11655-012-1120-0. Epub 2012 Jul 22. Review.
Yang B, Liu P Composition and biological activities of hydrolyzable tannins of fruits of Phyllanthus emblica. J Agric Food Chem. 2014 Jan 22;62(3):529-41. doi: 10.1021/jf404703k. Epub 2014 Jan 9. Review.
Zhang LZ, Zhao WH, Guo YJ, Tu GZ, Lin S, Xin LG [Studies on chemical constituents in fruits of Tibetan medicine Phyllanthus emblica]. Zhongguo Zhong Yao Za Zhi. 2003 Oct;28(10):940-3. Chinese.
Effect of Amla Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.